Lytix and KAEL-GemVax link up for cancer immunotherapy
This article was originally published in Scrip
Executive Summary
Lytix Biopharma and South Korea's KAEL-GemVax are to initiate a joint clinical trial with a novel cancer immunotherapy which combines their respective lead development projects.